Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. / Mensberg, Pernille; Nyby, Signe; Jørgensen, Peter Godsk; Storgaard, H; Jensen, Magnus Thorsten; Sivertsen, J; Holst, Jens Juul; Kiens, Bente; Richter, Erik A.; Knop, Filip Krag; Lauritsen, Tina Vilsbøll.

I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 2, 2017, s. 172-180.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Mensberg, P, Nyby, S, Jørgensen, PG, Storgaard, H, Jensen, MT, Sivertsen, J, Holst, JJ, Kiens, B, Richter, EA, Knop, FK & Lauritsen, TV 2017, 'Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, bind 19, nr. 2, s. 172-180. https://doi.org/10.1111/dom.12797

APA

Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., ... Lauritsen, T. V. (2017). Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 19(2), 172-180. https://doi.org/10.1111/dom.12797

Vancouver

Mensberg P, Nyby S, Jørgensen PG, Storgaard H, Jensen MT, Sivertsen J o.a. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2017;19(2):172-180. https://doi.org/10.1111/dom.12797

Author

Mensberg, Pernille ; Nyby, Signe ; Jørgensen, Peter Godsk ; Storgaard, H ; Jensen, Magnus Thorsten ; Sivertsen, J ; Holst, Jens Juul ; Kiens, Bente ; Richter, Erik A. ; Knop, Filip Krag ; Lauritsen, Tina Vilsbøll. / Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. I: Diabetes, Obesity and Metabolism. 2017 ; Bind 19, Nr. 2. s. 172-180.

Bibtex

@article{869d73fab88049a6a6acbec4265f46af,
title = "Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes",
abstract = "Aims: Exercise as well as glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment improves glycaemic control in patients with type 2 diabetes. We investigated the effects of exercise in combination with a GLP-1RA (liraglutide) or placebo for the treatment of type 2 diabetes.Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training.Results: HbA1c levels dropped by 2.0 ± 1.2{\%} (mean ± standard deviation) (from 8.2 ± 1.4{\%}) in the exercise plus liraglutide group vs 0.3 ± 0.9{\%} (from 8.0 ± 1.2{\%}) with exercise plus placebo (p < 0.001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 vs -1.6 ± 2.3 kg, p < 0.001). Compared to baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5 ± 1.4{\%}, (p < 0.001); exercise plus placebo: -2.2 ± 1.9{\%}, (p < 0.001)) and similar increases were observed in maximal oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 l O2 per min (p < 0.001); exercise plus placebo: 0.4 ± 0.4 l O2 per min (p = 0.002)). Greater reductions in fasting plasma glucose (-3.4 ± 2.3 vs -0.3 ± 2.6 mM, p < 0.001) and systolic blood pressure (-5.4 ± 7.4 vs -0.6 ± 11.1 mmHg, p < 0.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention.Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalised HbA1c levels and caused a robust weight loss when compared to placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.",
keywords = "Faculty of Science, Exercise, GLP-1, GLP-1 receptor agonist, Glucagon-like peptide-1, Liraglutide, Randomized study, Type 2 diabetes",
author = "Pernille Mensberg and Signe Nyby and J{\o}rgensen, {Peter Godsk} and H Storgaard and Jensen, {Magnus Thorsten} and J Sivertsen and Holst, {Jens Juul} and Bente Kiens and Richter, {Erik A.} and Knop, {Filip Krag} and Lauritsen, {Tina Vilsb{\o}ll}",
note = "CURIS 2017 NEXS 036",
year = "2017",
doi = "10.1111/dom.12797",
language = "English",
volume = "19",
pages = "172--180",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

AU - Mensberg, Pernille

AU - Nyby, Signe

AU - Jørgensen, Peter Godsk

AU - Storgaard, H

AU - Jensen, Magnus Thorsten

AU - Sivertsen, J

AU - Holst, Jens Juul

AU - Kiens, Bente

AU - Richter, Erik A.

AU - Knop, Filip Krag

AU - Lauritsen, Tina Vilsbøll

N1 - CURIS 2017 NEXS 036

PY - 2017

Y1 - 2017

N2 - Aims: Exercise as well as glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment improves glycaemic control in patients with type 2 diabetes. We investigated the effects of exercise in combination with a GLP-1RA (liraglutide) or placebo for the treatment of type 2 diabetes.Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training.Results: HbA1c levels dropped by 2.0 ± 1.2% (mean ± standard deviation) (from 8.2 ± 1.4%) in the exercise plus liraglutide group vs 0.3 ± 0.9% (from 8.0 ± 1.2%) with exercise plus placebo (p < 0.001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 vs -1.6 ± 2.3 kg, p < 0.001). Compared to baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5 ± 1.4%, (p < 0.001); exercise plus placebo: -2.2 ± 1.9%, (p < 0.001)) and similar increases were observed in maximal oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 l O2 per min (p < 0.001); exercise plus placebo: 0.4 ± 0.4 l O2 per min (p = 0.002)). Greater reductions in fasting plasma glucose (-3.4 ± 2.3 vs -0.3 ± 2.6 mM, p < 0.001) and systolic blood pressure (-5.4 ± 7.4 vs -0.6 ± 11.1 mmHg, p < 0.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention.Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalised HbA1c levels and caused a robust weight loss when compared to placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.

AB - Aims: Exercise as well as glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment improves glycaemic control in patients with type 2 diabetes. We investigated the effects of exercise in combination with a GLP-1RA (liraglutide) or placebo for the treatment of type 2 diabetes.Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training.Results: HbA1c levels dropped by 2.0 ± 1.2% (mean ± standard deviation) (from 8.2 ± 1.4%) in the exercise plus liraglutide group vs 0.3 ± 0.9% (from 8.0 ± 1.2%) with exercise plus placebo (p < 0.001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 vs -1.6 ± 2.3 kg, p < 0.001). Compared to baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5 ± 1.4%, (p < 0.001); exercise plus placebo: -2.2 ± 1.9%, (p < 0.001)) and similar increases were observed in maximal oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 l O2 per min (p < 0.001); exercise plus placebo: 0.4 ± 0.4 l O2 per min (p = 0.002)). Greater reductions in fasting plasma glucose (-3.4 ± 2.3 vs -0.3 ± 2.6 mM, p < 0.001) and systolic blood pressure (-5.4 ± 7.4 vs -0.6 ± 11.1 mmHg, p < 0.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention.Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalised HbA1c levels and caused a robust weight loss when compared to placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.

KW - Faculty of Science

KW - Exercise

KW - GLP-1

KW - GLP-1 receptor agonist

KW - Glucagon-like peptide-1

KW - Liraglutide

KW - Randomized study

KW - Type 2 diabetes

U2 - 10.1111/dom.12797

DO - 10.1111/dom.12797

M3 - Journal article

C2 - 27717126

VL - 19

SP - 172

EP - 180

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

ID: 167474168